Navigation Links
Delcath Systems Receives Refusal to File Letter From FDA
Date:2/22/2011

NEW YORK, Feb. 22, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the Company has received a "refusal to file" letter from the U.S. Food & Drug Administration (FDA) for the New Drug Application (NDA) for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride.  Delcath expects to submit a formal meeting request to the FDA this week and intends to meet with the FDA at the earliest opportunity to discuss the issues raised and to confirm our understanding of the remedies required for the filing to be accepted.  Based on management's current understanding of the information in the FDA's letter, the Company intends to resubmit the NDA by September 30, 2011.  

In accordance with application regulations, the FDA has the ability to formally file or refuse to file an application within 60 days of the completion of the submission, which occurred on December 22, 2010.  Neither the acceptance nor non-acceptance of the NDA filing is a determination of the approvability of the chemosaturation system.

"The FDA's letter requested information involving manufacturing plant inspection timing, product and sterilization validations and additional safety information that we already planned on filing with our 120 day safety update in April, as well as additional statistical analysis clarification," said Eamonn P. Hobbs, CEO & President of Delcath Systems. "We believe that we will be able to provide the requested information in an updated application and we expect to resubmit the NDA by the end of the third quarter of this year.  In the meantime, the CE Mark Technical File review process for marketing approval of the Hepatic ChemoSAT™ Delivery System continues on schedule.  Our expec
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Delcath Achieves ISO 13485 Certification
2. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
3. Delcath Systems Announces Third Quarter Progress Report Conference Call
4. Delcath Strengthens Research and Development Team with Key Appointments
5. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
6. Delcath to Present at the William Blair Emerging Growth Stock Conference
7. Delcath to Present at the JMP Securities Healthcare Conference
8. Delcath Systems Announces Completion of Common Stock Offering
9. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
10. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
11. Delcath Systems Announces Second Quarter Progress Report Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... today announced that it will report its 2013 first quarter earnings on ... Ed Borkowski , CFO, will host an analyst and ... To participate in the conference call within the U.S. and ... conference call outside the U.S. and Canada , dial ... Participants should dial in 10 minutes prior to the start of the ...
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... , May 17, 2013 Oramed ... of oral drug delivery systems, announced today that the ... the Company,s Investigational New Drug application(IND) for ORMD-0801, its ... to have the FDA clearance to proceed," stated ... upcoming trial is a major milestone for Oramed and ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3
... Male Hypogonadism, LEXINGTON, Mass., Aug. 28 ... that it has submitted,a New Drug Application (NDA) ... approval for NEBIDO(R) (testosterone undecanoate) intramuscular,injection, a long-acting ... and secondary hypogonadism. Each 1000 mg injection of,NEBIDO ...
... Corporation,(Nasdaq: CRGN ) and TopoTarget A/S (Copenhagen ... dosing in a Phase I/II clinical,trial evaluating belinostat ... the anthracycline idarubicin for the,treatment of Acute Myeloid ... sites in the European Union. Patients under ...
Cached Medicine Technology:Indevus Announces Submission of New Drug Application 2Indevus Announces Submission of New Drug Application 3Indevus Announces Submission of New Drug Application 4Indevus Announces Submission of New Drug Application 5Indevus Announces Submission of New Drug Application 6CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 2CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 3CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 4CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 5CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia 6
(Date:5/19/2013)... 19, 2013 According to a ... and Forecast (2013 – 2018): By Applications (Healthcare ... Technology (CCD, CMOS, Contact IS, Infrared, X-Ray) And ... sensor market was $8.00 billion in 2012 and ... at an estimated CAGR of 3.84% from 2013 ...
(Date:5/19/2013)... 19, 2013 The Pradaxa lawyers at ... was recently convened for hundreds of Pradaxa bleeding ... underway in U.S. District Court, Southern District of Illinois. ... on May 14th, the Conference addressed the status of ... during the Conference that Defendants submitted a list of ...
(Date:5/19/2013)... Vegas, Nevada (PRWEB) May 19, 2013 ... agency , is proud to announce the launch it's ... Awards at the MGM Grand on 5/19/2013. Consumers traveling ... all new special pricing available on VegasHotelEscapes.com's website. Travelers ... that they beat any competitors price. , Vegas Hotel ...
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
(Date:5/19/2013)... Raton, FL (PRWEB) May 19, 2013 ... launched the website YazSideEffects.com in a concerted effort to ... of the combination birth control drugs Yaz, Yasmin & ... offers a wealth of information on the notorious birth ... lawsuits against Bayer Pharmaceuticals. , Yaz, Yasmin & ...
Breaking Medicine News(10 mins):Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 2Health News:Image Sensors Market to Reach $10.75 Billion by 2018 at a CAGR of 3.84% - New Report by MarketandMarkets 3Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 2Health News:Pradaxa Lawyers at Bernstein Liebhard LLP Report on Recent Status Conference in Federal Pradaxa Litigation 3Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Yazsideeffects.com Connects Yaz Side Effects Sufferers With Yaz Side Effects Lawyers 2
... and the good fats in Omega-3 fatty acids help new ... the issue of the International Breastfeeding Journal. ... affecting anywhere from 10 percent to 20 percent of postpartum ... as high as 40 percent or 50 percent. Since depression ...
... the home clearly raise the risk of the allergic sensitisation ... older children , however, the influence of the environment at ... This is the conclusion reached by scientists from the GSF ... ,The study published by Chih-Mei Chen et ...
... New Jersey The nations publicized gay governor, James E. McGreevy ... he has managed to be in the news for ... and has become an Episcopalian. ,Former Gov. James E. ... officially inducted into the Episcopal religion on Sunday at St. ...
... here have developed a device that can enable the blind to ... it costs Rs.2,000-3,000 and it reads texts through an embedded system ... ,Right now it can only read text, but ... ,The Agra College team that took six months to ...
... to the information furnished by Indira Gandhi National Open ... of Parliament/State legislature or deemed to be university ... of norms and guidelines laid down by the Distance ... its meeting held on March 23, 2007 had resolved ...
... state representatives from 105 countries met Friday to formally adopt ... impacts of global warming after five days of heated debate ... discussions ended at 3:30 a.m. Friday," said Carloa Traverso Saibante, ... (IPCC). ,Once the IPCC report is formally adopted, ...
Cached Medicine News:Health News:Breastfeeding and Omega-3 Fatty Acids Help New Moms Fight Depression 2Health News:Cats at Home Poses Allergy Risk in Young Children 2Health News:Climate Talks Reach Consensus in Bangkok 2
... Revolutions start with small things. The ... one of the trailblazers of the ... the,trend towards ever smaller access and ... operation site. ,The HiLAN XS motor ...
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
The stereotactic frame has been specifically designed for a radiosurgery procedure and can be used instead of traditional expensive frames....
... The basic frame, consisting of one part only, ... fixations of highly compressed Polyamide may be rotated ... to all head sizes and shapes, as well. ... frame far enough in caudal direction, which is ...
Medicine Products: